Welcome to our dedicated page for PHH news (Ticker: PHH), a resource for investors and traders seeking the latest updates and insights on PHH stock.
Park Ha Biological Technology Co., Ltd. (historically Nasdaq: PHH) generates news that reflects both its consumer-focused skincare operations and its status as a foreign private issuer listed on a U.S. exchange. The company is primarily engaged in developing its private skincare label, direct skincare product sales, and franchise alliance promotions under its proprietary "Park Ha" brand, with a focus on cost-effective solutions to skin problems and improving the confidence of women seeking skin treatment.
News related to Park Ha Biological Technology Co., Ltd. has included capital markets milestones such as the pricing and closing of its initial public offering of ordinary shares on the Nasdaq Capital Market. These announcements have detailed the number of shares offered, the public offering price, and the company’s stated uses of proceeds, including expanding directly owned stores in the People’s Republic of China, purchasing existing product patents to develop proprietary products, and acquiring ingredient suppliers to reduce long-term production costs.
Investors following PHH-related coverage can also find updates on corporate actions and listing status. The company has reported receiving Nasdaq notifications regarding deficiencies in the minimum closing bid price requirement and the minimum market value of listed securities requirement, outlining the compliance periods and potential measures, such as a reverse stock split, that may be considered to regain compliance. In addition, Park Ha Biological Technology Co., Ltd. has announced a change of its Nasdaq trading symbol from "PHH" to "BYAH" to avoid confusion with a delisted company that previously used the same symbol, while stating that its ordinary shares will continue to be listed on Nasdaq and that no action is required by existing shareholders.
Other news items may include disclosures about annual general meetings, shareholder voting outcomes on matters such as dual-class share structures and share consolidations, and changes in board composition, such as the resignation of an independent director. For readers interested in the intersection of consumer skincare brands and U.S.-listed foreign issuers, the PHH news feed provides a record of Park Ha Biological Technology Co., Ltd.’s public communications and regulatory-related developments.
Park Ha Biological Technology (NASDAQ: BYAH) closed a best-efforts follow-on offering of 21,875,000 units at US$0.112 per unit on January 28, 2026, generating approximately US$2.45 million in gross proceeds.
Each unit includes one Class A ordinary share and one warrant exercisable at US$0.112 through the one-year anniversary, with an alternative cashless exercise allowing up to nine shares. Net proceeds are intended to fund expansion of directly operated stores in China.
Park Ha Biological Technology (NASDAQ: BYAH) priced a best-efforts follow-on offering of 21,875,000 units at US$0.112 per unit, with each unit containing one Class A ordinary share and one warrant (warrants exercisable at US$0.112 or via zero-price option up to nine shares). The company expects aggregate gross proceeds of US$2.45 million before placement agent commissions and expenses. Warrants are exercisable from issuance until the one-year anniversary. Closing is expected on or about January 28, 2026, subject to customary conditions. The company intends to use net proceeds to expand directly operated stores in China. D. Boral Capital LLC is sole placement agent and the offering is made under an effective Form F-1 registration statement.
Park Ha Biological Technology (NASDAQ: PHH) will change its Nasdaq ticker symbol to BYAH, effective Tuesday, October 28, 2025. Trading of the Company’s ordinary shares will move from the symbol PHH to BYAH on that date. The Company said the change aims to avoid confusion with a delisted issuer that previously used PHH and to strengthen long-term brand value. No action is required by existing shareholders. The Company will remain listed on Nasdaq and the CUSIP will remain unchanged. The announcement contains standard forward-looking statement disclaimers about risks and uncertainties.
Park Ha Biological Technology (Nasdaq: PHH) has successfully completed its Initial Public Offering, raising $4.8 million through the sale of 1,200,000 ordinary shares at $4.00 per share. Trading began on the Nasdaq Capital Market on December 27, 2024, under the symbol 'PHH'.
The company, which specializes in private skincare labels, direct sales, and franchise alliance promotions, has granted underwriters a 45-day option to purchase up to 180,000 additional shares. The net proceeds will be used to expand directly-owned stores in China, purchase product patents for proprietary development, and acquire ingredient suppliers to reduce production costs.
Dawson James Securities and D. Boral Capital served as underwriters for this firm commitment offering.
Park Ha Biological Technology, a Chinese skincare company, announced the pricing of its Initial Public Offering (IPO) of 1,200,000 ordinary shares at $4.00 per share, expecting to raise $4.8 million in gross proceeds. The shares will trade on the Nasdaq Capital Market under symbol PHH starting December 27, 2024.
The underwriters have a 45-day option to purchase up to 180,000 additional shares. The IPO proceeds will fund expansion of directly-owned stores in China, purchase of product patents for proprietary products, and acquisition of ingredient suppliers to reduce production costs. Dawson James Securities and D. Boral Capital are serving as underwriters for the offering, which is expected to close around December 30, 2024.